Chloroprocaine
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Chloroprocaine: From Local Anesthesia to Cauda Equina Syndrome
One-Sentence Summary
Chloroprocaine is a short-acting local anesthetic, marketed in the US as an injectable solution and an ophthalmic gel. The TxGNN model predicts it may be relevant to cauda equina syndrome, but the 1 clinical trial and 4 publications found all describe this condition as a complication of neuraxial anesthesia, not something the drug treats. The prediction most likely reflects an adverse-event association, not a therapeutic one.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the US label data provided (local anesthetic) |
| Predicted New Indication | Cauda equina syndrome |
| TxGNN Prediction Score | 99.01% |
| Evidence Level | L5 (model prediction only; the retrieved studies are safety reports, not efficacy evidence. The source pack labels this L4.) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 11 license records (NDA009435, NDA216227) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the record. Chloroprocaine is a local anesthetic of the ester type, which blocks voltage-gated sodium channels and thereby interrupts nerve conduction.
No therapeutic link is supported. In the retrieved literature, cauda equina syndrome appears as a known complication of spinal and epidural anesthesia. Local anesthetic neurotoxicity, including with chloroprocaine, has been implicated. A drug that blocks nerve conduction has no known mechanism for treating a compressive or injury-related nerve-root disorder.
The high TxGNN score (0.99) most likely comes from a knowledge-graph connection through adverse events or anesthesia-related links. It should not be read as evidence of benefit. The prediction cannot be cross-checked against a known original mechanism or indication, because neither is available.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02067806 | N/A (observational) | Completed | 394 | Prospective safety study of 1% 2-chloroprocaine in spinal anesthesia, tracking neurological adverse events, especially transient neurological symptoms and cauda equina syndrome. It tests safety, not treatment, so it gives no direct support for this indication. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22236346 | 2012 | RCT | Acta Anaesthesiol Scand | Chloroprocaine vs lidocaine for selective spinal anesthesia in outpatient TURP. It compares anesthetic performance and does not address treating cauda equina syndrome. |
| 23320599 | 2013 | Review | Acta Anaesthesiol Scand | Review of chloroprocaine for spinal anesthesia. It notes that neurologic sequelae followed intrathecal injection of large doses of preservative-containing chloroprocaine. |
| 11368250 | 2001 | Review | Drug Saf | Incidence and prevention of regional anesthesia complications, including neural injury and local anesthetic toxicity. |
| 9338907 | 1997 | Case report | Reg Anesth | Two cases of cauda equina syndrome after spinal-epidural anesthesia. Prior reports had implicated lidocaine, chloroprocaine, and procaine. |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA009435 | Nesacaine | Injection, solution | Not listed in the data provided |
| NDA009435 | Chloroprocaine HCl | Injection, solution | Not listed in the data provided |
| NDA009435 | Chloroprocaine HCl | Injection, solution | Not listed in the data provided |
| NDA216227 | IHEEZO | Gel | Not listed in the data provided |
| NDA009435 | Nesacaine | Injection, solution | Not listed in the data provided |
Safety Considerations
The literature above raises a specific neurotoxicity concern. Cauda equina syndrome and transient neurological symptoms have been reported after intrathecal or epidural local anesthetics, including chloroprocaine, particularly with large doses of preservative-containing formulations.
Please refer to the package insert for other safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence describes cauda equina syndrome as a possible harm of neuraxial chloroprocaine, not a condition it treats. There is no efficacy evidence and no plausible mechanism for treatment, so the high model score is not actionable.
To proceed, the following is needed:
- Package insert warnings and contraindications, currently missing and blocking safety screening
- Mechanism of action data from DrugBank
- Expert review to confirm whether the prediction is an adverse-event artifact and should be dropped
- Any evidence of therapeutic benefit in cauda equina syndrome, which none of the retrieved studies provide
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.